5 big analyst AI moves: Apple lifted to Buy, AI chip bets reassessed
Reid Hoffman, a beneficial owner of Vor Biopharma Inc. (NASDAQ:VOR), and Reprogrammed Interchange LLC, sold a total of 37,533 shares of common stock between October 17 and October 21, 2025, for approximately $1.13 million. The sales prices ranged from $30.0535 to $31.00 per share, notably above the current trading price of $27.77. The stock has shown significant volatility with a beta of 2.08, while delivering an impressive 111% return over the past six months.
On October 17, 24,689 shares were sold at a weighted average price of $30.2207, with individual sales prices ranging from $30.00 to $30.88. An additional 1,028 shares were sold on the same day at $31.00 per share. On October 20, 11,616 shares were sold at a weighted average price of $30.0535, with prices ranging from $30.00 to $30.27. Finally, on October 21, 200 shares were sold at $30.075 per share. For deeper insights into insider trading patterns and comprehensive financial analysis, InvestingPro subscribers can access detailed reports and real-time alerts.
Following these transactions, Reprogrammed Interchange LLC, of which Reid Hoffman may be deemed a beneficial owner, holds 1,166,909 shares of Vor Biopharma Inc. common stock. The company, currently valued at $190.88 million, maintains a "Weak" overall financial health score according to InvestingPro analysis.
In other recent news, Vor Biopharma has reported several significant developments. The company, in collaboration with RemeGen, announced positive results from a Phase 3 trial of telitacicept for primary Sjögren’s disease. The trial, conducted in China, met both its primary and secondary endpoints, showing substantial improvements in disease activity. Additionally, Baird upgraded Vor Biopharma’s stock rating from Neutral to Outperform, citing the promising potential of telitacicept. This upgrade was accompanied by a notable increase in the price target from $20.00 to $64.00. Vor Biopharma is also set to present the telitacicept data at the upcoming ACR Convergence 2025 conference. Meanwhile, the company filed a preliminary prospectus for the potential resale of up to 50,999,999 shares of its common stock, which includes shares issuable to RemeGen’s subsidiary and other investors. These recent developments highlight Vor Biopharma’s active engagement in advancing its therapeutic offerings and financial strategies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.